Self-Nanoemulsifying 3D-Printed Tablet for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 3D printed drug delivery systems face challenges with limited oral bioavailability due to inadequate aqueous solubility and dissolution rates, leading to significant drug loss during absorption, particularly through the first-pass metabolism phenomenon.
Innovation Solution
A self-nanoemulsifying 3D printer ink composition incorporating glimepiride and rosuvastatin in a curcuma oil-based self-nanoemulsifying drug delivery system (SNEDDS) with specific ratios of curcuma oil, surfactants, co-surfactants, and hydroxypropyl methylcellulose, designed to enhance bioavailability and customize drug release rates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional 3D printed drug delivery systems are used, then manufacturing flexibility and personalization are improved, but oral bioavailability deteriorates due to inadequate aqueous solubility and dissolution rates
Solution Approach 1:
The patent transforms the physical-chemical parameters of the drug formulation by incorporating SNEDDS technology, which changes the drug delivery system from conventional solid dosage forms to self-nanoemulsifying liquid crystals. This parameter change enables the formulation to spontaneously form nanoemulsions in the gastrointestinal tract, dramatically improving aqueous solubility and dissolution rates while maintaining 3D printing manufacturing flexibility
Solution Approach 2:
The patent creates a composite material system by combining 3D printed tablet structure with SNEDDS encapsulated active pharmaceutical ingredients. The composite consists of the printed matrix containing oil-in-water nanoemulsion droplets, surfactants, and co-surfactants, which work synergistically to provide both manufacturing personalization and enhanced oral bioavailability
2Quantity of substance
If drug concentration is increased to improve therapeutic effect, then treatment effectiveness is improved, but drug loss during first-pass metabolism increases
Solution Approach 1:
The patent utilizes phase transition phenomena where the SNEDDS formulation transitions from a liquid crystal state in the printed tablet to spontaneous nanoemulsion formation upon contact with gastrointestinal fluids. This phase transition enhances drug solubility and absorption efficiency, reducing the amount of drug lost during first-pass metabolism while maintaining therapeutic concentration
3Ease of manufacture
If conventional dosage forms are used, then manufacturing simplicity is maintained, but dissolution rates and absorption efficiency deteriorate
Solution Approach 1:
The patent implements self-service functionality where the SNEDDS formulation automatically self-assembles into nanoemulsions upon contact with gastrointestinal fluids without requiring external energy input or complex processing. This self-emulsifying property maintains manufacturing simplicity while dramatically accelerating dissolution rates and improving absorption efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly improves bioavailability and allows for personalized drug release profiles, enhancing the effectiveness of 3D printed tablets by optimizing the bioavailability and dissolution rates of glimepiride and rosuvastatin.
Implementation Method 1
a self-nanoemulsifying 3D printer ink composition incorporating glimepiride and rosuvastatin in a curcuma oil-based self-nanoemulsifying drug delivery system (SNEDDS)
Data Source
AI summary
Provided are a self-nanoemulsifying 3D printer ink composition and a method of using such composition to manufacture a 3D-printed tablet having compartmentalized active pharmaceutical ingredients. In particular, the 3D-printed tablet composition includes glimepiride and/or rosuvastatin in a curcuma oil based self-nanoemulsifying drug delivery system (SNEDDS).